An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
about
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesHistone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo.High efficiency of alphaviral gene transfer in combination with 5-fluorouracil in a mouse mammary tumor model.The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.High glucose-induced resistance to 5-fluorouracil in pancreatic cancer cells alleviated by 2-deoxy-D-glucose.E1A-engineered human umbilical cord mesenchymal stem cells as carriers and amplifiers for adenovirus suppress hepatocarcinoma in mice.Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials.AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinomaThe combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model.Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes.Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells.The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11ING4 expressing oncolytic vaccinia virus promotes anti-tumor efficiency and synergizes with gemcitabine in pancreatic cancer.In Vitro Synergistic Enhancement of Newcastle Disease Virus to 5-Fluorouracil Cytotoxicity against Tumor Cells.A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.Combination of interferon-expressing oncolytic adenovirus with chemotherapy and radiation is highly synergistic in hamster model of pancreatic cancer.Designer Oncolytic Adenovirus: Coming of Age.
P2860
Q26863779-D934CA96-FB51-4F58-9342-2C7B6C8C3765Q30354691-AA8A9570-B144-4DBF-984E-01F512AA285EQ33828697-CA3452A4-D1B7-4B53-8A91-398C8770986EQ36738884-3CE95A67-B247-4C85-AEDC-40FBBF2FAF9EQ37567719-BBFA7B74-5265-490A-9326-0442F6100D9AQ37588372-C3FE326C-1450-4F91-9960-B3FD12276107Q38033591-90451A93-7664-4AC5-8D70-E8743570CC52Q38223419-2ECD704A-EDD1-4D0F-8B12-1C5D6FA98D06Q38237657-F3CEED9D-D817-4EC3-9DD7-8E1985B0BE94Q38645375-7C3A7818-D9C2-424F-B42F-1F32DA896794Q38847702-428ECD6F-C0BF-4822-9FF8-04732EDEF31BQ38964488-CC1572DA-EE9A-4F32-A50B-E767CB59C6EDQ39033731-AB69536F-D3EE-4A00-A351-06AAE55786ADQ39359422-636668F0-7E49-4F2B-8B76-6E3FE5671ADDQ40160910-03D8C3C4-B24D-4DF9-B55C-AF34411E5713Q40913003-F390ADF8-DF7E-4226-B5AD-046DFD2066A0Q45324859-4903D73B-4D73-426E-9499-235468E4234DQ50905634-148EAEB6-B6B4-4069-A6AA-869B1D03AB04Q54975352-804301FF-2D64-44A4-95A9-AFDE9A2BC418Q55004955-B0B525F5-0711-4F96-879E-DDE80F54E10FQ55467684-CAECD665-A13D-44DC-9911-30E4BD3D0887
P2860
An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
An oncolytic adenovirus defect ...... tion with 5-FU or gemcitabine.
@en
An oncolytic adenovirus defective in pRb-binding
@nl
type
label
An oncolytic adenovirus defect ...... tion with 5-FU or gemcitabine.
@en
An oncolytic adenovirus defective in pRb-binding
@nl
prefLabel
An oncolytic adenovirus defect ...... tion with 5-FU or gemcitabine.
@en
An oncolytic adenovirus defective in pRb-binding
@nl
P2093
P2860
P356
P1433
P1476
An oncolytic adenovirus defect ...... ation with 5-FU or gemcitabine
@en
P2093
P2860
P2888
P304
P356
10.1038/CGT.2011.45
P577
2011-08-12T00:00:00Z